NYSEARCA:GRN iPath Series B Carbon ETN (GRN) Price, Holdings, & News $32.09 -0.33 (-1.02%) (As of 10/2/2023 ET) Add Compare Share Share Today's Range$32.04▼$32.1950-Day Range$32.05▼$36.4152-Week Range$25.38▼$39.02Volume6,190 shsAverage Volume6,781 shsMarket Capitalization$94.29 millionAssets Under Management$45.37 millionDividend Yield0.00%Net Expense Ratio0.75% ProfileProfileChartHeadlinesProfileChartHeadlines GRN Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GRN ETF News HeadlinesSeptember 30, 2023 | americanbankingnews.comiPath Series B Carbon ETN (NYSEARCA:GRN) Share Price Passes Below Two Hundred Day Moving Average of $34.34September 11, 2023 | wsj.comBergman & Beving AB Series BOctober 3, 2023 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>July 30, 2023 | benzinga.comiPath Series B Carbon Exchange-Traded Notes Stock (ARCA:GRN), Quotes and News SummaryJuly 4, 2023 | wsj.comSagax AB Series BSeptember 20, 2022 | cnbc.comBarclays iPath Series B S&P 500 VIX Short-Term FuturesApril 27, 2022 | finance.yahoo.comKraneShares Debuts Carbon Offset ETFJanuary 4, 2022 | finance.yahoo.comBest Performing ETFs of 2021October 3, 2023 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?" One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see 113,000% gains! Get the name of the stock here >>>December 16, 2021 | finance.yahoo.comBest ETFs for Q1 2022See More Headlines Receive GRN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iPath Series B Carbon ETN and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerBarclays Capital Fund NameiPath Series B Carbon ETN Tax ClassificationExchange-Traded Note Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:GRN Inception Date9/11/2019 Fund ManagerN/A Webwww.barclays.co.uk Phone442071161000Fund Focus Asset ClassEquity BenchmarkBarclays Global Carbon II TR USD Index CategoryStrategy FocusTheme Development LevelDeveloped Markets RegionGlobal Number of Holdings0 Fund Statistics Assets Under Management$45.37 million Average Daily Volume$0.00 Discount/Premium-0.08% Administrator, Advisor and Custodian AdministratorN/A AdvisorN/A CustodianN/A DistributorN/A Transfer AgentN/A TrusteeN/A Lead Market MakerJane Street Options OptionableOptionable Options Volume1 Put Options1 Call Options1 Miscellaneous Outstanding Shares2,938,000BetaN/A 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report iPath Series B Carbon ETN ExpensesTypeGRNTheme ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.00%0.57%0.53%0.50%0.50%Other Expenses0.00%0.78%0.52%0.64%0.57%Total Expense0.00%0.73%0.69%0.74%0.69%Fee Waiver0.00%-0.81%-0.55%-0.69%-0.58%Net Expense0.75%0.60%0.59%0.57%0.57% iPath Series B Carbon ETN (GRN)Full Holdings Details Similar ETFsiShares ESG MSCI EM Leaders ETFNASDAQ:LDEMGod Bless America ETFNYSEARCA:YALLWahed Dow Jones Islamic World ETFNASDAQ:UMMAGoldman Sachs Manufacturing Revolution ETFNYSEARCA:GMANInspire Faithward Mid Cap Momentum ETFNYSEARCA:GLRYInstitutional OwnershipFlow Traders U.S. LLCBought 15,431 shares on 8/9/2023Ownership: 0.525%Simplex Trading LLCBought 663,200 shares on 8/4/2023Ownership: 0.000%View All Institutional Transactions GRN ETF - Frequently Asked Questions How have GRN shares performed in 2023? iPath Series B Carbon ETN's stock was trading at $31.63 at the beginning of the year. Since then, GRN shares have increased by 1.5% and is now trading at $32.0917. View the best growth stocks for 2023 here. What does GRN invest in? iPath Series B Carbon ETN is a equity fund issued by Barclays Capital. GRN focuses on theme investments and follows the Barclays Global Carbon II TR USD Index. The fund's investments total to approximately $45.37 million assets under management. What other stocks do shareholders of iPath Series B Carbon ETN own? Based on aggregate information from My MarketBeat watchlists, some companies that other iPath Series B Carbon ETN investors own include Synopsys (SNPS), Sondrel (SND), Marathon Oil (MRO), Electronic Arts (EA) and What is iPath Series B Carbon ETN's stock symbol? iPath Series B Carbon ETN trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "GRN." How do I buy shares of iPath Series B Carbon ETN? Shares of GRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is iPath Series B Carbon ETN's stock price today? One share of GRN stock can currently be purchased for approximately $32.09. How much money does iPath Series B Carbon ETN make? iPath Series B Carbon ETN (NYSEARCA:GRN) has a market capitalization of $94.29 million. How many employees does iPath Series B Carbon ETN have? The company employs 2,020 workers across the globe. How can I contact iPath Series B Carbon ETN? iPath Series B Carbon ETN's mailing address is Canary Wharf, 1 Churchill Place, London E14 5HP. The official website for the company is www.barclays.co.uk. The exchange traded fund can be reached via phone at 442071161000. This page (NYSEARCA:GRN) was last updated on 10/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iPath Series B Carbon ETN Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.